Absence of early platelet increment in healthy mice during decitabine treatment

Sci Rep. 2022 Dec 23;12(1):22266. doi: 10.1038/s41598-022-26821-8.


Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however, is understudied. We show that an early platelet increment was not detectable in healthy mice during decitabine treatment. Analyses of bone marrow sections revealed vessels with dilated lumina, decreased cellularity, but increased number of red blood cells and the presence of (pro)platelet-like particles. Taken together, decitabine treatment of healthy mice does not induce an early platelet increment, but affects the bone marrow.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azacitidine* / pharmacology
  • Azacitidine* / therapeutic use
  • Blood Platelets
  • Decitabine / pharmacology
  • Megakaryocytes
  • Mice
  • Myelodysplastic Syndromes*
  • Treatment Outcome


  • Decitabine
  • Azacitidine